Responses

Download PDFPDF
Abatacept in relapsing polychondritis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Authors' response re:Abatacept in relapsing polychondritis

    Dear Editor,

    We were pleased to learn of Moulis et al.'s update on their experience with abatacept in three RP patients, particularly since their disease manifestations reflected the same manifestations suggested in our study to be of greatest interest for abatacept: chondritis and peripheral arthritis. Interestingly one patient achieved a complete, while another achieved only a partial, corticosteroid-sparing...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Abatacept in relapsing polychondritis
    • Guillaume Moulis
    • Other Contributors:
      • Gregory Pugnet, Laurent Sailler, Leonardo Astudillo, and Philippe Arlet

    Dear Editor,

    We read with great interest the open clinical trial of four relapsing polychondritis (RP) patients treated with abatacept by Peng and Rodriguez recently published in the Annals of the Rheumatic Diseases (1). Indeed, as the authors pointed out, there is rational to block T-cell pathway in this disease, though the biologic agents most used as second-line therapy after corticosteroids (CS) are pro-inflamm...

    Show More
    Conflict of Interest:
    None declared.